<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The optimal first-line treatment for symptomatic patients with advanced stage follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> remains unclear </plain></SENT>
<SENT sid="1" pm="."><plain>Fludarabine-based combination regimens have been extensively used in <z:e sem="disease" ids="C0277556" disease_type="Disease or Syndrome" abbrv="">relapsed disease</z:e> and merit consideration as first-line therapy </plain></SENT>
<SENT sid="2" pm="."><plain>We here report the results of a phase II study of <z:chebi fb="18" ids="16238">FAD</z:chebi> (fludarabine, adriamycin, <z:chebi fb="0" ids="41879">dexamethasone</z:chebi>) regimen in 30 patients with advanced stage follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> requiring treatment </plain></SENT>
<SENT sid="3" pm="."><plain>The response rate was in excess of 90% with 39% achieving a complete remission </plain></SENT>
<SENT sid="4" pm="."><plain>The major toxicity was <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e>, but only 3% of cycles were associated with grade IV <z:e sem="disease" ids="C0023530" disease_type="Disease or Syndrome" abbrv="">leucopenia</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>The high response rate has not translated into major improvements in failure-free survival and consideration must be given to alternative treatment modalities to consolidate the high rate of initial responses </plain></SENT>
</text></document>